Sign In  |  Register  |  About Walnut Creek Guide  |  Contact Us

Walnut Creek, CA
September 01, 2020 1:43pm
7-Day Forecast | Traffic

  • Search Hotels in Walnut Creek Guide

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Puretech Health Plc ADR (NQ: PRTC )

22.21 -1.18 (-5.04%)
Streaming Delayed Price Updated: 12:56 PM EST, Nov 29, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Puretech Health Plc ADR

< Previous 1 2 3 4 5 6 7 8 9 Next >
PureTech Founded Entity Seaport Therapeutics Adds Sandi Peterson to its Board of Directors
From PureTech Health plc
Via Business Wire
PureTech Founded Entity Seaport Therapeutics Names Lauren White as Chief Financial Officer
From PureTech Health plc
Via Business Wire
PureTech to Present at Two Upcoming Investor Conferences
From PureTech Health
Via Business Wire
PureTech Founded Entity Seaport Therapeutics Closes $225 Million Oversubscribed Series B Financing Round
From PureTech Health plc
Via Business Wire
PureTech Presents Research Highlighting Burden of Idiopathic Pulmonary Fibrosis (IPF) and Use of a Bayesian Statistical Analysis for LYT-100 (Deupirfenidone) at CHEST 2024 Annual Meeting
From PureTech Health plc
Via Business Wire
PureTech to Present at CHEST 2024 Annual Meeting
From PureTech Health
Via Business Wire
Schizophrenia Treatment Revolution: FDA Approves Bristol Myers Squibb' Cobenfy As New Class Of Treatment In More Than 3 Decades
Bristol Myers Squibb's Cobenfy has been approved by the FDA as the first new treatment for schizophrenia in decades. The medication introduces a new approach by targeting M1 and M4 receptors without... 
Via Benzinga
Exposures Product Safety
PureTech-Invented KarXT Receives U.S. Food and Drug Administration Approval for the Treatment of Schizophrenia in Adults
From PureTech Health plc
Via Business Wire
Rubrik Reports Q2 Results, Joins Ionis Pharmaceuticals, Hewlett Packard Enterprise And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Via Benzinga
PureTech Founded Entity Vor Bio Announces New Clinical Data Validating Approach of Using Shielded Transplants to Deliver Targeted Therapies
From PureTech Health plc
Via Business Wire
Boeing, Dyne Therapeutics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Via Benzinga
PureTech Health plc – Half-Year Report
From PureTech Health plc
Via Business Wire
Galapagos, XPeng, CorMedix And Other Big Stocks Moving Higher On Monday
Via Benzinga
PureTech Appoints Michele Holcomb, PhD, to Board of Directors
From PureTech Health plc
Via Business Wire
PureTech Health: Notice of Half-Yearly Results
From PureTech Health plc
Via Business Wire
PureTech Founded Entity Seaport Therapeutics Appoints David Wheadon, M.D., to its Board of Directors
From PureTech Health plc
Via Business Wire
PureTech Founded Entity Vedanta Biosciences Expands Leadership Team and Appoints Head of Commercial
From PureTech Health plc
Via Business Wire
PureTech Health: Completion of Tender Offer & Total Voting Rights
From PureTech Health plc
Via Business Wire
PureTech Health: Results of the Tender Offer
From PureTech Health plc
Via Business Wire
PureTech Announces Change of Board Role
From PureTech Health plc
Via Business Wire
PureTech Founded Entity Seaport Therapeutics Appoints Seasoned Executives to Management Team
From PureTech Health plc
Via Business Wire
PureTech Health: Results of Annual General Meeting
From PureTech Health plc
Via Business Wire
PureTech Health: Result of General Meeting
From PureTech Health plc
Via Business Wire
PureTech Founded Entity Akili Interactive and Virtual Therapeutics Announce Entering Into Definitive Merger Agreement to Establish Leading Digital Health Company
From PureTech Health plc
Via Business Wire
PureTech to Present at the Jefferies Global Healthcare Conference
From PureTech Health plc
Via Business Wire
PureTech Founded Entity Vedanta Biosciences Enrolls First Patient in Pivotal Phase 3 RESTORATiVE303 Study of VE303 for the Prevention of Recurrent C. difficile Infection
From PureTech Health plc
Via Business Wire
PureTech Health: Launch of Proposed $100 Million Tender Offer at 250 Pence Per Ordinary Share
From PureTech Health plc
Via Business Wire
PureTech Founded Entity Seaport Therapeutics Presents Data from Multiple SPT-300 Trials at Society of Biological Psychiatry (SOBP) Annual Meeting
From PureTech Health plc
Via Business Wire
PureTech Founded Entity Seaport Therapeutics Adds Industry Veteran to Board of Directors and Makes Key Executive Appointments
From PureTech Health plc
Via Business Wire
PureTech Announces Annual Results for Year Ended December 31, 2023
From PureTech Health plc
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 WalnutCreekGuide.com & California Media Partners, LLC. All rights reserved.